These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 35921524)

  • 41. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
    Nesic K; Krais JJ; Wang Y; Vandenberg CJ; Patel P; Cai KQ; Kwan T; Lieschke E; Ho GY; Barker HE; Bedo J; Casadei S; Farrell A; Radke M; Shield-Artin K; Penington JS; Geissler F; Kyran E; Betsch R; Xu L; Zhang F; Dobrovic A; Olesen I; Kristeleit R; Oza A; McNeish I; Ratnayake G; Traficante N; ; DeFazio A; Bowtell DDL; Harding TC; Lin K; Swisher EM; Kondrashova O; Scott CL; Johnson N; Wakefield MJ
    Mol Cancer; 2024 Aug; 23(1):158. PubMed ID: 39103848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
    Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
    Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    Pham MM; Hinchcliff E; Avila M; Westin SN
    Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
    Kristeleit RS; Moore KN
    Ann Oncol; 2022 Oct; 33(10):989-991. PubMed ID: 35964823
    [No Abstract]   [Full Text] [Related]  

  • 45. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    Tao M; Wu X
    J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
    Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
    Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    Miller RE; El-Shakankery KH; Lee JY
    J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
    Hiroki H; Akahane K; Inukai T; Morio T; Takagi M
    Int J Hematol; 2023 May; 117(5):748-758. PubMed ID: 36575328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    Konstantinopoulos PA; Cheng SC; Supko JG; Polak M; Wahner-Hendrickson AE; Ivy SP; Bowes B; Sawyer H; Basada P; Hayes M; Curtis J; Horowitz N; Wright AA; Campos SM; Ivanova EV; Paweletz CP; Palakurthi S; Liu JF; D'Andrea AD; Gokhale PC; Chowdhury D; Matulonis UA; Shapiro GI
    Br J Cancer; 2022 Apr; 126(7):1027-1036. PubMed ID: 34887522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
    Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.